Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 biologic product, jinnamab. This marks a significant milestone for the company as it progresses in the development of this innovative treatment.
Jinnamab, an anti-IL-1β antibody, is currently in various stages of clinical investigation for conditions such as systemic juvenile idiopathic arthritis and interstitial lung disease. The molecule has shown promise in addressing these diseases and is also anticipated for its potential use in acute gouty arthritis, for which it awaits its first regulatory decision in China.
This development follows a successful clinical trial approval in the United States in June 2022, where jinnamab was granted permission to be assessed as a potential treatment for adult onset still disease. The biologic product’s progress underscores Changchun High & New Technology Industries’ commitment to advancing novel therapies and expanding its global footprint in the biopharmaceutical sector.- Flcube.com
